Trial Profile
A 12 week, randomised, double blind study evaluating the effects of low-dose (10 mg) and high-dose (80 mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by ultra small super-paramagnetic iron oxide (USPIO) enhanced carotid magnetic resonance imaging (MRI)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary) ; Ferumoxtran-10
- Indications Atherosclerosis
- Focus Biomarker; Therapeutic Use
- Acronyms ATHEROMA
- Sponsors GlaxoSmithKline; GSK
- 03 Feb 2012 Results of the MRI analysis (n=26) presented at the 37th International Stroke Conference.
- 02 Jun 2009 Results were published in the Journal of the American College of Cardiology.
- 21 Apr 2008 The expected completion date for this trial is now 1 Aug 2007.